Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07922226
PHASE2/PHASE3

A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial

Sponsor: Minervax ApS

View on ClinicalTrials.gov

Summary

The main objective of the Phase 2 part of the trial is to assess the immunogenicity of GBS-NN/NN2 vaccine at birth in infant participants and to determine the occurrence of serious adverse events (SAEs) and adverse event of special interest (AESIs) after GBS-NN/NN2 vaccine administration compared to placebo, in both maternal and infant participants. The main objective of the Phase 3 part of the trial is to assess the ability of GBS-NN/NN2 vaccine to induce functional antibody titres protective against invasive GBS (iGBS) early-onset disease (EoD) in infant participants, to assess the ability of GBS-NN/NN2 vaccine to induce functional antibody titres protective against iGBS late-onset disease (LoD) in infant participants and to determine the occurrence of SAEs and AESIs after GBS-NN/NN2 vaccine administration compared to placebo, in both maternal and infant participants.

Official title: A Multicentre, Parallel-group, Observer-blind, Randomised, Placebo-controlled, Pivotal Trial Investigating the Safety and Immunogenicity of Group B Streptococcus Vaccine (GBS-NN/NN2) in Pregnant Women and Infants Born to Pregnant Women Vaccinated During Pregnancy

Key Details

Gender

FEMALE

Age Range

18 Years - 49 Years

Study Type

INTERVENTIONAL

Enrollment

6600

Start Date

2026-11-30

Completion Date

2030-05-22

Last Updated

2026-11-06

Healthy Volunteers

Yes

Interventions

DRUG

GBS-NN/NN2 vaccine

GBS-NN/NN2 contains 50 μg of each fusion protein (GBS-NN and GBS-NN2) in combination with 500 μg aluminium.

OTHER

Placebo

Placebo contains 0.9% sodium chloride.